{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:22:56Z","timestamp":1782336176077,"version":"3.54.5"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T00:00:00Z","timestamp":1497830400000},"content-version":"vor","delay-in-days":169,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Clinical studies comparing the different neuraminidase inhibitors for treatment of at-risk patients with influenza have not been performed. To optimize such treatments, we assessed the efficacy and safety of intravenous peramivir compared with oral oseltamivir in treating seasonal influenza A or B virus infection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A multicenter, randomized, controlled clinical trial was conducted from December 2012 to May 2014 in high-risk patients infected with seasonal influenza. A total of 92 adult inpatients and outpatients with high risk factors (HRFs) were treated by either a single intravenous infusion of peramivir (600 mg) or oral administration of oseltamivir (75 mg, twice per day for 5 days).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The median times to clinical stability (time to reach &amp;lt;37\u00b0C) were 40.0 hours (95% confidence interval [CI] = 23.3\u201364.5) and 37.8 hours (95% CI = 26.3\u201345.3) in the peramivir and oseltamivir groups, respectively; these values did not reveal a significant difference. The virus titer and change of mean total symptom scores decreased similarly with both treatments. Results of step-wise regression suggested that virus type was a significantly effective prognostic factor with respect to illness resolution. Adverse events (AEs) with peramivir and oseltamivir occurred in 2.2% (n = 1\/46) and 13.0% (n = 6\/46) of patients, respectively. The severity of AEs was mild in all cases except 2 patients who showed pneumonia or COPD aggravation; both were in the oseltamivir group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Intravenous peramivir was effective based on the result of direct comparison with oral oseltamivir. Thus our data show that peramivir is a useful option for the treatment of influenza-infected patients with HRFs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofx129","type":"journal-article","created":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T14:51:07Z","timestamp":1497883867000},"source":"Crossref","is-referenced-by-count":32,"title":["Efficacy and Safety of Intravenous Peramivir Compared With Oseltamivir in High-Risk Patients Infected With Influenza A and B Viruses: A Multicenter Randomized Controlled Study"],"prefix":"10.1093","volume":"4","author":[{"given":"Shigeki","family":"Nakamura","sequence":"first","affiliation":[{"name":"Department of Respiratory Diseases, Nagasaki University Hospital"},{"name":"Department of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiga","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, Nagasaki University Hospital"},{"name":"Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Izumikawa","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kakeya","sequence":"additional","affiliation":[{"name":"Department of Infection Control Science, Graduate School of Medicine, Osaka City University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Saisho","sequence":"additional","affiliation":[{"name":"Medical Affairs, Shionogi & Co, Ltd, Osaka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Yanagihara","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences , and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitsugu","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, Nagasaki University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Kohno","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, Nagasaki University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,6,19]]},"reference":[{"key":"2020081005185279000_CIT0001","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/infdis\/jis726","article-title":"Impact of neuraminidase inhibitor treatment on outcomes of public health Importance during the 2009\u20132010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients","volume":"207","author":"Muthuri","year":"2013","journal-title":"J Infect Dis"},{"key":"2020081005185279000_CIT0002","first-page":"76","article-title":"Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies","volume":"7","author":"Hsu","year":"2013","journal-title":"Ann Intern Med"},{"key":"2020081005185279000_CIT0003","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","article-title":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data","volume":"2","author":"Muthuri","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2020081005185279000_CIT0004","volume-title":"WHO Guidelines for Pharmacological Management of Pandemic (H1N1) 2009 Influenza and other Influenza Viruses","author":"World Health Organization"},{"key":"2020081005185279000_CIT0005","doi-asserted-by":"crossref","first-page":"834181","DOI":"10.1155\/2012\/834181","article-title":"Clinical effectiveness of peramivir in comparison with other neuraminidase inhibitors in pediatric influenza patients","volume":"2012","author":"Hikita","year":"2012","journal-title":"Int J Pediatr"},{"key":"2020081005185279000_CIT0006","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s10156-012-0428-1","article-title":"Clinical effectiveness of neuraminidase inhibitors\u2014oseltamivir, zanamivir, laninamivir, and peramivir\u2014for treatment of influenza A(H3N2) and A(HINl) pdm09 infection: an observational study in the 2010\u20132011 influenza season in Japan","volume":"18","author":"Shobugawa","year":"2012","journal-title":"J Infect Chemother"},{"key":"2020081005185279000_CIT0007","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000362436","article-title":"Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012\u20132013","volume":"59","author":"Takemoto","year":"2013","journal-title":"Chemotherapy"},{"key":"2020081005185279000_CIT0008","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3851\/IMP2798","article-title":"Comparison between virus shedding and fever duration after treating children with pandemic A H1N1\/09 and children with A H3N2 with a neuraminidase inhibitor","volume":"20","author":"Sugaya","year":"2015","journal-title":"Antivir Ther"},{"key":"2020081005185279000_CIT0009","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1128\/AAC.01718-10","article-title":"Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients","volume":"55","author":"Kohno","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081005185279000_CIT0010","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1164\/ajrccm.182.9.1209","article-title":"Peramivir for severe influenza infection in a patient with diabetic nephropathy","volume":"182","author":"Nasu","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2020081005185279000_CIT0011","article-title":"Effects of corticosteroid and neuraminidase inhibitors on survival in patients with respiratory distress induced by influenza virus","volume-title":"J Microbiol Immunol Infect","author":"Hung","year":"2015"},{"key":"2020081005185279000_CIT0012","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.antiviral.2008.05.012","article-title":"Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice","volume":"80","author":"Boltz","year":"2008","journal-title":"Antiviral Res"},{"key":"2020081005185279000_CIT0013","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3851\/IMP2744","article-title":"The effect of intravenous peramivir, compared with oral oseltamivir, on the outcome of post-influenza pneumococcal pneumonia in mice","volume":"20","author":"Tanaka","year":"2015","journal-title":"Antivir Ther"},{"key":"2020081005185279000_CIT0014","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1128\/AAC.02324-12","article-title":"Efficacy of repeated intravenous infection of peramivir against influenza A (H1N1) 2009 virus injection in immunosuppressed mice","volume":"57","author":"Kitano","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081005185279000_CIT0015","doi-asserted-by":"crossref","DOI":"10.3851\/IMP3104","article-title":"Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects","author":"Saisho","year":"2016","journal-title":"Antivir Ther"},{"key":"2020081005185279000_CIT0016","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1128\/AAC.00360-11","article-title":"Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection","volume":"55","author":"Kohno","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081005185279000_CIT0017","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2165\/00044011-200323090-00002","article-title":"Clinical benefits with oseltamivir in treating influenza in adult populations: results of a pooled and subgroup analysis","volume":"23","author":"Singh","year":"2003","journal-title":"Clin Drug Investig"},{"key":"2020081005185279000_CIT0018","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/jac\/dkq012","article-title":"Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients","volume":"65","author":"Dutkowski","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2020081005185279000_CIT0019","first-page":"55","article-title":"Influenza infection and COPD","volume":"2","author":"Patrick","year":"2007","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2020081005185279000_CIT0020","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/523584","article-title":"Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada","volume":"45","author":"McGeer","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020081005185279000_CIT0021","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/thx.2009.130799","article-title":"Outcomes of adults hospitalised with severe influenza","volume":"65","author":"Lee","year":"2010","journal-title":"Thorax"},{"key":"2020081005185279000_CIT0022","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/INF.0b013e318232ede9","article-title":"Oseltamivir shortens hospital stays of critically ill children hospitalized with seasonal influenza: a retrospective cohort study","volume":"30","author":"Coffin","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"2020081005185279000_CIT0023","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1086\/600383","article-title":"Viral loads and duration of viral shedding in adult patients hospitalized with influenza","volume":"200","author":"Lee","year":"2009","journal-title":"J Infect Dis"},{"key":"2020081005185279000_CIT0024","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1093\/cid\/ciu632","article-title":"Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients","volume":"59","author":"de Jong","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020081005185279000_CIT0025","doi-asserted-by":"crossref","first-page":"e40261","DOI":"10.1371\/journal.pone.0040261","article-title":"Use of intravenous peramivir for treatment of severe influenza A(H1N1)pdm09","volume":"7","author":"Louie","year":"2012","journal-title":"PLoS One"},{"key":"2020081005185279000_CIT0026","author":"Division of Acquired Immunodeficiency Syndrome"},{"key":"2020081005185279000_CIT0027","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1128\/AAC.00474-10","article-title":"Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection","volume":"54","author":"Kohno","year":"2010","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/4\/3\/ofx129\/33622661\/ofx129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/4\/3\/ofx129\/33622661\/ofx129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T09:26:33Z","timestamp":1597051593000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofx129\/3870490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofx129","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017]]},"published":{"date-parts":[[2017]]},"article-number":"ofx129"}}